Unraveling LGALS1 as a Potential Immune Checkpoint and a Predictor of the Response to Anti-PD1 Therapy in Clear Cell Renal Carcinoma

Pathology oncology research: POR

article

Li, Yan¹  Yang, Shouyan²  Yue, Honggang²  Yuan, Dandi²  Li, Luxia²  Zhao, Jinghong¹  Zhao, Lintao¹ 

[1] Department of Nephrology, Institute of Nephrology of Chongqing and Kidney Center of PLA, Xinqiao Hospital, Army Medical University (Third Military Medical University);Department of Oncology of the 958th Hospital, Southwest Hospital, Army Medical University (Third Military Medical University)

关键词: Immunotherapy;    PD-L1;    LGALS1;    Galectin1;    Clear cell renal carcinoma;    Immune checkpoint;   

DOI  :  10.1007/s12253-019-00710-4

来源: Springer

【 摘 要 】

Immunotherapy base on immune checkpoint inhibitor had obtained significant progress in extending the survival of clear cell renal carcinoma (ccRCC) patients. In order to further improve the efficiency of immunotherapy, novel immune checkpoint inhibitors needed to be developed. Differentially expressed genes (DEGs) between healthy kidney tissues and ccRCC tissues had been found from GSE68417 by GEO2R online analysis tool. Correlation analysis and Kaplan–Meier survival analyses were based on UALCAN database. Analyses of the outcome of anti-PD1 treatment had been found from GSE67501 dataset. At first, 9 genes with higher expression were associated with shorter overall survival time. More importantly, higher expression of LGALS1 was correlated with a profitable outcome of anti-PD1 treatment and the combined the expression level of PD-L1 and LGALS1 together could more efficiently predict the outcome of anti-PD1 treatment than using PD-L1 alone. At last, the genes which correlated with LGALS1 expression in ccRCC patients were enriched in TNF alpha Signaling Pathway which is mainly correlated with T cell apoptosis and survival. Together, these suggest LGALS1 could be a potential immune checkpoint, which could promote tumor progression through affecting T cell survival.

【 授权许可】

Unknown